Neurorepair with mesenchymal stem cells: hope or hype?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.PloS one · 2018
   Trial
2. Nanowired Delivery of Cerebrolysin with Mesenchymal Stem Cells Attenuates Heat Stress-Induced Exacerbation of Neuropathology Following Brain Blast Injury.Advances in neurobiology · 2023
   Article
3. A compendious summary of Parkinson's disease patient-derived iPSCs in the first decade.Annals of translational medicine · 2019
   Review
4. Effects ofNeural regeneration research · 2019
   Article
5. Synergistic Improvement in Children with Cerebral Palsy Who Underwent Double-Course Human Wharton's Jelly Stem Cell Transplantation.Stem cells international · 2019
   Article
6. Cerebrospinal fluid-stem cell interactions may pave the path for cell-based therapy in neurological diseases.Stem cell research & therapy · 2018
   Review
7. Human mesenchymal stem cells target adhesion molecules and receptors involved in T cell extravasation.Stem cell research & therapy · 2015
   Article
8. Patient heal thyself: modeling and treating neurological disorders using patient-derived stem cells.Experimental biology and medicine (Maywood, N.J.) · 2013
   Review

Corrections and comments

• Comment on
  Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.2012

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as